A study presented at ACR Convergence 2025 has sparked interest among doctors and patients alike. Drugs originally made for ...
MedPage Today on MSN
T-Cell Killer Opens New Approach to Rheumatoid Arthritis
Rosnilimab acts as an agonist to stimulate PD-1, killing those cells with high PD-1 expression and pushing others into an ...
MedPage Today on MSN
Difficult-to-Treat Rheumatoid Arthritis: Is Prevention Feasible?
CHICAGO -- Hitting rheumatoid arthritis (RA) early and hard, with targeted therapies as first-line treatment, appears to ...
New research presented at ACR 2025 shows GLP-1 receptor agonists, used for diabetes and obesity, may reduce rheumatoid ...
Several factors — but not older age — increased infection risk with the use of non-TNF biologics following first-line ...
The study also presented the first external validation and use in patients with early RA of six proposed screening strategies ...
"UK regulators seize illegal weight loss drugs amid global pricing shake-up" was originally created and published by ...
The new biotech Elevara plans to initiate Phase II testing of its lead candidate ELV001 as an add-on treatment for rheumatoid ...
Electra Therapeutics has garnered the funds it needs to complete a pivotal trial of its lead drug, angling to become the ...
Prioritization of refractory rheumatoid arthritis (RA) as lead indication for AlloNK® development FDA Fast Track Designation received for AlloNK ...
A study presented at ACR Convergence 2025 suggests that GLP 1 receptor agonists reduce flares and systemic inflammation in Rheumatoid Arthritis (RA) patients.
Patients with rheumatoid arthritis increased their leg muscle volume when treated with an anti-rheumatic drug, offering new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback